Henry F. Mcfarland

Henry F. Mcfarland's AcademicInfluence.com Rankings

Henry F. Mcfarland

Medical

#2429

World Rank

#2854

Historical Rank

Neurology

#232

World Rank

#310

Historical Rank

medical Degrees

Henry F. Mcfarland

Philosophy

#7052

World Rank

#10205

Historical Rank

Logic

#4131

World Rank

#5386

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Henry F. Mcfarland's Degrees

Doctorate Medicine Johns Hopkins University

Why Is Henry F. Mcfarland Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Henry F. Mcfarland's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis (2001) (6788)
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” (2005) (5003)
Multiple sclerosis: a complicated picture of autoimmunity (2007) (1028)
Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand (2000) (809)
Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. (1998) (632)
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. (2006) (599)
Association of human herpes virus 6 (HHV-6) with multiple sclerosis: Increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA (1997) (478)
Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients (2005) (466)
Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. (1995) (410)
Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis (1993) (397)
Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. (1990) (366)
Identification of High Potency Microbial and Self Ligands for a Human Autoreactive Class II–restricted T Cell Clone (1997) (355)
Using gadolinium‐enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis (1992) (341)
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. (2004) (320)
Serial gadolinium‐enhanced magnetic resonance imaging scans in patients with early, relapsing‐remitting multiple sclerosis: Implications for clinical trials and natural history (1991) (316)
A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis (1991) (285)
The effect of interferon‐β on blood—brain barrier disruptions demonstrated by constrast‐enhanced magnetic resonance imaging in relapsing—remitting multiple sclerosis (1995) (251)
Expansion and Functional Relevance of High-Avidity Myelin-Specific CD4+ T Cells in Multiple Sclerosis (2004) (247)
CD4+CD28- costimulation-independent T cells in multiple sclerosis. (2001) (242)
Analysis of gene expression in multiple sclerosis lesions using cDNA microarrays (1999) (236)
Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease (1999) (235)
The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative (2016) (225)
Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. (2003) (218)
Measles virus-specific T4+ human cytotoxic T cell clones are restricted by class II HLA antigens. (1984) (215)
Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study. (2004) (211)
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis (2010) (200)
HLA class II-restricted presentation of cytoplasmic measles virus antigens to cytotoxic T cells (1989) (197)
Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. (2003) (188)
Complex immunomodulatory effects of interferon‐β in multiple sclerosis include the upregulation of T helper 1‐associated marker genes (2001) (185)
Predictable TCR antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology. (1998) (184)
Tissue distribution and variant characterization of human herpesvirus (HHV)-6: increased prevalence of HHV-6A in patients with multiple sclerosis. (2000) (176)
Increases in soluble VCAM‐1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon β‐1b (1997) (174)
Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. (2003) (169)
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. (2009) (168)
Multiple sclerosis : clinical and pathogenetic basis (1997) (163)
Diversity in fine specificity and T cell receptor usage of the human CD4+ cytotoxic T cell response specific for the immunodominant myelin basic protein peptide 87-106. (1992) (158)
Magnetic resonance imaging of labeled T‐cells in a mouse model of multiple sclerosis (2004) (156)
Relationship of cortical atrophy to fatigue in patients with multiple sclerosis. (2010) (146)
The germline repertoire of T cell receptor β-chain genes in patients with chronic progressive multiple sclerosis (1989) (145)
Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions (2001) (145)
T helper 1 (Th1) functional phenotype of human myelin basic protein-specific T lymphocytes. (1993) (143)
Gender differences in autoimmune demyelination in the mouse: Implications for multiple sclerosis (1996) (143)
Age-dependent resistance to viral encephalitis: studies of infections due to Sindbis virus in mice. (1972) (138)
Characterization of MRI response to treatment with interferon beta-1b: Contrast-enhancing MRI lesion frequency as a primary outcome measure (1997) (132)
Skewed T-cell receptor repertoire in genetically identical twins correlates with multiple sclerosis (1993) (129)
Increased lymphoproliferative response to human herpesvirus type 6A variant in multiple sclerosis patients (2000) (129)
Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis (2001) (126)
VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta (1997) (123)
Multiple sclerosis in twins (1980) (123)
The role of MRI as a surrogate outcome measure in multiple sclerosis (2002) (117)
Immunodominance of a low-affinity major histocompatibility complex-binding myelin basic protein epitope (residues 111-129) in HLA-DR4 (B1*0401) subjects is associated with a restricted T cell receptor repertoire. (1997) (116)
Hereditary adult-onset leukodystrophy simulating chronic progressive multiple sclerosis. (1984) (116)
Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS (1998) (113)
Molecular mimicry and multiple sclerosis: Degenerate T‐cell recognition and the induction of autoimmunity (1999) (111)
Human autoreactive CD4+ T cell clones use perforin- or Fas/Fas ligand-mediated pathways for target cell lysis. (1997) (109)
Training-dependent plasticity in patients with multiple sclerosis. (2004) (106)
Modifications of peptide ligands enhancing T cell responsiveness imply large numbers of stimulatory ligands for autoreactive T cells. (1997) (104)
The Immune Response to Viruses (1989) (104)
Differential activation of human autoreactive T cell clones by altered peptide ligands derived from myelin basic protein peptide (87–99) (1996) (103)
Blood‐brain barrier disruption on contrast‐enhanced MRI in patients with mild relapsing‐remitting multiple sclerosis (1995) (102)
Serial contrast‐enhanced magnetic resonance imaging in patients with early relapsing–remitting multiple sclerosis: Implications for treatment trials (1994) (101)
Susceptibility for multiple sclerosis is determined, in part, by inheritance of a 175-kb region of the TcR Vβ chain locus and HLA class II genes (1993) (95)
Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. (2009) (94)
In vivo detection of cortical plaques by MR imaging in patients with multiple sclerosis. (2006) (92)
SPECIFICITY OF THE INFLAMMATORY RESPONSE IN VIRAL ENCEPHALITIS (1972) (92)
Preferential expansion of autoreactive T lymphocytes from the memory T-cell pool by IL-7 (1999) (90)
Megadose corticosteroids in multiple sclerosis (1994) (88)
Immunopathogenesis of the multiple sclerosis lesion (2001) (87)
A pilot study of recombinant insulin-like growth factor-1 in seven multiple sclerosis patients (2002) (85)
Central nervous system disease in primary Sjögren’s syndrome: The role of magnetic resonance imaging (2004) (84)
Analysis of gene expression in mutiple sclerosis lesions using cDNA microarrays. (1999) (83)
Multiple sclerosis: Re‐expression of a developmental gene in chronic lesions correlates with remyelination (1997) (83)
Intrathecal effects of daclizumab treatment of multiple sclerosis (2011) (83)
Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease (1997) (82)
Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders. (2003) (82)
Identification of a novel T cell epitope of human proteolipid protein (residues 40–60) recognized by proliferative and cytolytic CD4+ T cells from multiple sclerosis patients (1993) (82)
Increased serum levels of soluble CD95 (APO‐1/Fas) in relapsing‐remitting multiple sclerosis (1998) (80)
Interferon beta results in immediate reduction of contrast‐enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI (1997) (80)
Immunologic analysis of a spinal cord-biopsy specimen from a patient with human T-cell lymphotropic virus type I-associated neurologic disease. (1997) (80)
Copolymer-1-induced inhibition of antigen-specific T cell activation: interference with antigen presentation (1992) (79)
Immunotherapy of multiple sclerosis: Where are we? Where should we go? (2001) (78)
Study of relapsing remitting experimental allergic encephalomyelitis SJL mouse model using MION‐46L enhanced in vivo MRI: Early histopathological correlation (1998) (77)
Antiserums to neurons and to oligodendroglia from mammalian brain. (1977) (75)
Identification of endothelin 2 as an inflammatory factor that promotes central nervous system remyelination. (2013) (75)
Interferon‐β1a therapy in human T‐lymphotropic virus type I–associated neurologic disease (2005) (75)
Molecular mimicry and antigen-specific T cell responses in multiple sclerosis and chronic CNS Lyme disease. (2001) (74)
Contribution of Individual Amino Acids Within MHC Molecule or Antigenic Peptide to TCR Ligand Potency1 (2000) (73)
VLA-4/CD49d downregulated on primed T lymphocytes during interferon-β therapy in multiple sclerosis (2000) (71)
Minimal peptide length requirements for CD4(+) T cell clones--implications for molecular mimicry and T cell survival. (2000) (71)
A novel population of CD4+CD56+ myelin-reactive T cells lyses target cells expressing CD56/neural cell adhesion molecule. (1996) (70)
Serial whole-brain magnetization transfer imaging in patients with relapsing-remitting multiple sclerosis at baseline and during treatment with interferon beta-1b. (1998) (69)
Reduction in HTLV‐I proviral load and spontaneous lymphoproliferation in HTLV‐I–associated myelopathy/tropical spastic paraparesis patients treated with humanized anti‐tac (1998) (68)
In vitro studies of cell-mediated immunity in an acute viral infection. (1974) (68)
Human Autoreactive CD4+ T Cells from Naive CD45RA+ and Memory CD45RO+ Subsets Differ with Respect to Epitope Specificity and Functional Antigen Avidity (2000) (67)
Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing–remitting multiple sclerosis (1999) (67)
T cell recognition of myelin proteolipid protein and myelin proteolipid protein peptides in the peripheral blood of multiple sclerosis and control subjects (1998) (67)
Impaired measles virus-specific cytotoxic T cell responses in multiple sclerosis (1985) (67)
Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFN&bgr;-1b (2002) (66)
MRI as a marker for disease heterogeneity in multiple sclerosis (2005) (66)
Cytokine gene expression in cells derived from CSF of multiple sclerosis patients (1998) (66)
Age dependence of clinical and pathological manifestations of autoimmune demyelination. Implications for multiple sclerosis. (1999) (65)
HLA-DR2a is the dominant restriction molecule for the cytotoxic T cell response to myelin basic protein in DR2Dw2 individuals. (1990) (65)
Identification of an epitope derived from human proteolipid protein that can induce autoreactive CD8+ cytotoxic T lymphocytes restricted by HLA-A3: evidence for cross-reactivity with an environmental microorganism (1997) (63)
Two mechanisms of antigen-specific apoptosis of myelin basic protein (MBP)-specific T lymphocytes derived from multiple sclerosis patients and normal individuals. (1995) (62)
Inhibitors of dipeptidyl peptidase IV/CD26 suppress activation of human MBP-specific CD4+ T cell clones (1998) (61)
Complexities in the Treatment of Autoimmune Disease (1996) (61)
The effect of measles virus infection on T and B lymphocytes in the mouse. I. Suppression of helper cell activity. (1974) (60)
T cell response to myelin basic protein in the context of the multiple sclerosis-associated HLA-DR15 haplotype: peptide binding, immunodominance and effector functions of T cells (1997) (60)
Intravenous antigen adrmnistration as a therapy for autoimmune demyelinating disease (1996) (60)
Elevated serum and cerebrospinal fluid levels of soluble human herpesvirus type 6 cellular receptor, membrane cofactor protein, in patients with multiple sclerosis (2001) (59)
Myelin basic protein‐specific T‐cell responses in identical twins discordant or concordant for multiple sclerosis (1993) (59)
Cytokine phenotype of human autoreactive T cell clones specific for the immunodominant myelin basic protein peptide (83–99) (1996) (58)
The B cell--old player, new position on the team. (2008) (58)
Induction of subacute murine measles encephalitis by monoclonal antibody to virus haemagglutinin (1981) (56)
Clinical and pathological features of an autosomal dominant, adult-onset leukodystrophy simulating chronic progressive multiple sclerosis. (1994) (55)
Familial multiple sclerosis: Clinical, histocompatibility, and viral serological studies (1978) (55)
Antigen presentation to HLA class II-restricted measles virus-specific T-cell clones can occur in the absence of the invariant chain. (1988) (55)
Family and Twin Studies in Multiple Sclerosis (1984) (55)
The germline repertoire of T-cell receptor beta-chain genes in patients with multiple sclerosis. (1989) (54)
Kinematic specificity of cortical reorganization associated with motor training (2004) (54)
Chronic Relapsing Experimental Autoimmune Encephalomyelitis: Effects of Insulin‐like Growth Factor‐I Treatment on Clinical Deficits, Lesion Severity, Glial Responses, and Blood Brain Barrier Defects (1998) (53)
Time series for modelling counts from a relapsing-remitting disease: application to modelling disease activity in multiple sclerosis. (1994) (53)
Enhancing magnetic resonance imaging lesions and cerebral atrophy in patients with relapsing multiple sclerosis. (2001) (52)
Interferon-β interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific, T-helper type 1 lymphocytes (1997) (51)
Homologies between T cell receptor junctional sequences unique to multiple sclerosis and T cells mediating experimental allergic encephalomyelitis. (1994) (50)
Ring-enhancement in multiple sclerosis: marker of disease severity (2001) (49)
HPRT mutant T-cell lines from multiple sclerosis patients recognize myelin proteolipid protein peptides (1997) (49)
Use of magnetic resonance imaging in the diagnosis of multiple sclerosis (1986) (49)
Increased detection of serum HHV-6 DNA sequences during multiple sclerosis (MS) exacerbations and correlation with parameters of MS disease progression (2002) (48)
Unique Clinical and Pathological Features in HLA-DRB1*0401–restricted MBP 111–129–specific Humanized TCR Transgenic Mice (2004) (48)
Myelin Basic Protein-Specific TCR/HLA-DRB5*01:01 Transgenic Mice Support the Etiologic Role of DRB5*01:01 in Multiple Sclerosis (2012) (47)
FLAIR and magnetization transfer imaging of patients with post-treatment Lyme disease syndrome (2001) (47)
Human T‐cell lymphotropic virus type II–associated myelopathy: Clinical and immunologic profiles (1996) (47)
Computed tomography and magnetic resonance imaging in adult-onset leukodystrophy. (1988) (43)
Human T-cell response to myelin basic protein peptide (83-99): Extensive heterogeneity in antigen recognition, function, and phenotype (1997) (43)
Identification of a specific HLA DR2 Ia molecule as a restriction element for measles virus-specific HLA class II-restricted cytotoxic T cell clones (1985) (43)
Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood—brain barrier disruption in multiple sclerosis (2009) (41)
Citrulline‐containing myelin basic protein is recognized by T‐cell lines derived from multiple sclerosis patients and healthy individuals (1994) (41)
Measles virus persistence in human lymphocytes: a role for virus-induced interferon. (1982) (39)
T cell response to 2′,3′-cyclic nucleotide 3′-phosphodiesterase (CNPase) in multiple sclerosis patients (2002) (39)
Conventional magnetic resonance imaging features in patients with tropical spastic paraparesis (2005) (39)
Selective neuronal, dendritic, and postsynaptic localization of viral antigen in measles-infected mice. (1979) (38)
Expansion of antigen-specific T cells from cerebrospinal fluid of patients with multiple sclerosis (1983) (37)
Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosis (2006) (36)
Multiple sclerosis: Possible immunological mechanisms☆ (1989) (36)
Adult human glial cells can present target antigens to HLA-restricted cytotoxic T-cells (1990) (35)
Magnetic resonance techniques to monitor the long term evolution of multiple sclerosis pathology and to monitor definitive clinical trials. (1998) (34)
Epitope spreading occurs in active but not passive EAE induced by myelin basic protein (1996) (34)
Cellular immune response to measles, mumps, and vaccinia viruses in multiple sclerosis (1979) (33)
Experimental allergic encephalomyelitis induced by the peptide encoded by exon 2 of the MBP gene, a peptide implicated in remyelination (1994) (33)
Defective interfering particles modulate VSV infection of dissociated neuron cultures (1979) (33)
2′,3′-cyclic nucleotide 3′-phosphodiesterase: a novel candidate autoantigen in demyelinating diseases (1997) (32)
MRI and clinical activity in MS patients after terminating treatment with interferon beta-l b (2000) (32)
The response of human lymphocyte subpopulations to measles, mumps, and vaccinia viral antigens. (1980) (31)
Proton MR spectroscopic imaging in multiple sclerosis (2002) (31)
Extended observations on the association of HHV-6 and multiple sclerosis. (2000) (31)
Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations. (2005) (30)
Correlation of clinical features and findings on cranial magnetic resonance imaging with urinary myelin basic protein‐like material in patients with multiple sclerosis (1994) (29)
Central nervous system disease in primary Sjogrens syndrome: the role of magnetic resonance imaging. (2004) (29)
A novel candidate autoantigen in a multiplex family with multiple sclerosis: prevalence of T-lymphocytes specific for an MBP epitope unique to myelination (1993) (29)
Multiple Sclerosis: A Comprehensive Text (2008) (28)
T1 cortical hypointensities and their association with cognitive disability in multiple sclerosis (2010) (28)
Lessons from studies of antigen-specific T cell responses in Multiple Sclerosis. (2000) (28)
Twin studies and multiple sclerosis (1992) (27)
The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis. (2013) (27)
The Role of T Cells in Multiple Sclerosis: Implications for Therapies Targeting the T Cell Receptor (1994) (27)
Heterogeneity of T-cell receptor alpha-chain complementarity-determining region 3 in myelin basic protein-specific T cells increases with severity of multiple sclerosis. (1994) (27)
Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study. (2009) (27)
Multisequence-imaging protocols to detect cortical lesions of patients with multiple sclerosis: Observations from a post-mortem 3 Tesla imaging study (2009) (26)
ELI-spot of Th-1 cytokine secreting PBMC's in multiple sclerosis: correlation with MRI lesions (1998) (26)
Impaired human leukocyte antigen–restricted measles virus–specific cytotoxic T‐cell response in subacute sclerosing panencephalitis (1989) (25)
Expression pattern of activation and adhesion molecules on peripheral blood CD4+ T-lymphocytes in relapsing-remitting multiple sclerosis patients: a serial analysis (1996) (25)
Preliminary trial of poly ICLC in chronic progressive multiple sclerosis (1986) (25)
Response of human lymphocytes to measles virus after natural infection (1983) (24)
Measles virus-specific cellular immunity in patients with vaccine failure (1993) (24)
T-lymphocyte recognition of a portion of myelin basic protein encoded by an exon expressed during myelination (1993) (23)
Humoral and cellular immune responses to matrix protein of measles virus in subacute sclerosing panencephalitis (1988) (23)
Diseases Involving Myelin (1999) (23)
Estimating cerebral atrophy in multiple sclerosis patients from various MR pulse sequences (2002) (23)
Identification of a second T cell epitore of human proteolipid protein (residues 89–106) recognized by proliferative and cytolytic CD4+ T cells from multiple sclerosis patients (1994) (23)
CNS vasculitis in a patient with MS on daclizumab monotherapy (2013) (23)
New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab (2009) (23)
A functional basis for the association of HLA class II genes adn susceptibility to multiple sclerosis: cellular immune responses to myelin basic protein in a multiplex family (1993) (22)
CD 4 + CD 28 – costimulation-independent T cells in multiple sclerosis (2001) (22)
Induction of measles virus-specific human cytotoxic T cells by purified measles virus nucleocapsid and hemagglutinin polypeptides. (1987) (22)
Differential effects of phosphodiesterase type 4-specific inhibition on human autoreactive myelin-specific T cell clones (1999) (21)
Chronic measles encephalitis in mice. (1980) (21)
Antibody-mediated modification of encephalitis induced by hamster neurotropic measles virus. (1983) (21)
Immunology of Multiple Sclerosis (1988) (20)
Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: Reporting extended results from phase III clinical trials (1999) (20)
Adrenergic dysfunction in hereditary adult‐onset leukodystrophy (1987) (19)
Longitudinal study of myelin basic protein-specific T-cell receptors during the course of multiple sclerosis (1997) (19)
Oral administration of the nitroxide radical TEMPOL exhibits immunomodulatory and therapeutic properties in multiple sclerosis models (2017) (19)
Human antiidiotypic antibody against opiate receptors (1988) (18)
The future of multiple sclerosis therapies: redesigning multiple sclerosis clinical trials in a new therapeutic eraa (2005) (18)
Cortisol induction by poly ICLC: Implications for clinical trials of interferon (1988) (18)
T-cell response to myelin basic protein and lipid-bound myelin basic protein in patients with multiple sclerosis and healthy donors (1998) (18)
Correlation between MR and clinical findings of disease activity in multiple sclerosis. (1999) (17)
Human T lymphocytes specific for the immunodominant 83–99 epitope of myelin basic protein: Recognition of golli MBP HOG 7 (1996) (17)
Quality and Quantity of Diffuse and Focal White Matter Disease and Cognitive Disability of Patients with Multiple Sclerosis (2011) (16)
Subacute sclerosing panencephalitis after passive immunization and natural measles infection (1982) (16)
Effect of Anti-CD 25 Antibody Daclizumab in the Inhibition of Inflammation and Stabilization of Disease Progression in Multiple Sclerosis (2009) (16)
Examination of the role of magnetic resonance imaging in multiple sclerosis: A problem-orientated approach (2009) (16)
Erratum: Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β (Proceedings of the National Academy of Sciences of the United States of America (June 8, 2004) 101:23 (8705-8708)) (2004) (15)
HLA restriction and TCR usage of T lymphocytes specific for a novel candidate autoantigen, X2 MBP, in multiple sclerosis. (1994) (15)
Cerebrospinal fluid somatostatin, mood, and cognition in multiple sclerosis (1999) (15)
Measles virus-polypeptide specificity of the cytotoxic T-lymphocyte response in multiple sclerosis (1989) (15)
Induction of experimental allergic encephalomyelitis in the NIH minipig (2000) (15)
Polypeptide specificities of measles virus-reactive T cell lines and clones derived from a patient with multiple sclerosis. (1986) (15)
THE ROLE OF THE INFLAMMATORY RESPONSE IN VIRAL INFECTIONS (1975) (14)
Studies of multiple sclerosis in twins (1983) (14)
Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis (2005) (13)
DR2/DQwl Inheritance and haplotype sharing in affected siblings from multiple sclergis families (1996) (13)
Lymphocytapheresis in chronic progressive multiple sclerosis: Results of a preliminary trial (1983) (13)
Gene-Marked Autologous Hematopoietic Stem Cell Transplantation of Autoimmune Disease (2004) (13)
Ring and nodular multiple sclerosis lesions (2010) (13)
Retrovirus mediated gene transfer of the self antigen MBP into the bone marrow of mice alters resistance to experimental autoimmune encephalomyelitis (2000) (12)
The multiple sclerosis lesion (1995) (12)
Deficient expression in multiple sclerosis of the inhibitory transcription factor SP3 in mononuclear blood cells (1996) (12)
Linkage analysis in spinopontine atrophy: correlation of HLA linkage with phenotypic findings in hereditary ataxia. (1987) (11)
Recognition of Intracellular Measles Virus Antigens by HLA Class II Restricted Measles Virus‐Specific Cytotoxic T Lymphocytes (1988) (11)
In vivo three-dimensional MR microscopy of mice with chronic relapsing experimental autoimmune encephalomyelitis after treatment with insulin-like growth factor-I. (1998) (11)
Expression pro ® ling identi ® es responder and non-responder phenotypes to interferon-b in multiple sclerosis (2003) (11)
Virus‐Specific Cytotoxic T Cells in Multiple Sclerosis (1988) (10)
Clinical safety of serial monthly administrations of gadopentetate dimeglumine in patients with multiple sclerosis (1997) (10)
ATTEMPT TO ISOLATE INFECTIOUS AGENT FROM BONE-MARROW OF PATIENTS WITH MULTIPLE SCLEROSIS (1979) (10)
DR2/DQw1 inheritance and haplotype sharing in affected siblings from multiple sclerosis families. (1996) (10)
Contrast-enhanced MRI lesions during treatment with interferonβ-1b predict increase in T1 black hole volume in patients with relapsing-remitting multiple sclerosis (2005) (10)
Effects of viral infection on nervous system development. II. Attempts to modify bluetongue-virus-induced malformations with cyclophosphamide and antithymocyte serum. (1972) (10)
Lack of over-expression of T cell receptor Vβ5.2 in myelin basic protein-specific T cell lines derived from HLA-DR2 positive multiple sclerosis patients and controls (1998) (9)
Characterization of antigen-specific T cells in multiple sclerosis twins with elevated proliferative responses to measles virus. (1986) (8)
National Multiple Sclerosis Society Working Group on Neuroimaging for the Medical Advisory Board (1987) (8)
Experimental immunotherapies for multiple sclerosis (2004) (8)
Measles virus-specific human T cell clones: Studies of alloreactivity and antigenic cross-reactivity (1988) (8)
Impaired Measles‐Specific Cytotoxic T‐Cell Response in Subacute Sclerosing Panencephalitis (1988) (8)
Immunofluorescent Study of Circulating Antibody in Experimental Allergic Encephalomyelitis 1 (1970) (7)
MEASLES VIRUS INFECTION OF HUMAN PERIPHERAL BLOOD LYMPHOCYTES: IMPORTANCE OF THE OKT4+ T-CELL SUBSET1 (1984) (7)
Sjögren's syndrome mimicking multiple sclerosis (1990) (7)
Contrast-enhanced magnetic resonance activity in relapsing remitting multiple sclerosis patients: a short term natural history study (2000) (7)
In vitro modulation of human, autoreactive MBP-specific CD4+ T-cell clones by cyclosporin A (1997) (6)
Immunological Responses to Viruses in Multiple Sclerosis: Cell-mediated Immunity (1982) (6)
Natalizumab and immune cells. (2006) (6)
Infection of the central nervous system produced by R1 vesicular stomatitis virus. (1979) (6)
Acute encephalopathy caused by defective virus infection (1976) (6)
Monitoring relapsing remitting MS patients (1999) (6)
Multiple sclerosis: Are HLA class I molecules involved in disease pathogenesis? (1995) (6)
Characterization of Cerebrospinal Fluid Lymphocytes in Multiple Sclerosis a (1984) (6)
Multiple sclerosis patients have reduced HLA class II-restricted cytotoxic responses specific for both measles and herpes virus (1991) (5)
A pilot study of recombinant insulin-like growth factor-I in seven multiple sclerosis patients (2002) (5)
The path to damage in multiple sclerosis (1999) (5)
How to participate in a multiple sclerosis clinical trial. (2000) (4)
Diagnosis of multiple sclerosis. (2008) (4)
Semi-automatic segmentation and modeling of the cervical spinal cord for volume quantification in multiple sclerosis patients from magnetic resonance images (2008) (4)
Alemtuzumab versus interferon beta-1a: implications for pathology and trial design (2009) (4)
Use of magnetic resonance imaging in the diagnosis of multiple sclerosis. Policy statement of the National Multiple Sclerosis Society, New York (1986) (3)
The effect of interferon beta-1b on size of short-lived enhancing lesions in patients with multiple sclerosis (2008) (3)
Limited repertoire of HLA-DRB1*0401-restricted MBP111–129-specific T cells in HLA-DRB1*0401 Tg mice and their pathogenic potential (2004) (3)
Chapter 53 – Multiple Sclerosis (2003) (3)
Different Development of Myelin Basic Protein Agonist- and Antagonist-Specific Human TCR Transgenic T Cells in the Thymus and Periphery1 (2008) (3)
Manganese-Enhanced MRI in Patients with Multiple Sclerosis (2020) (3)
Regulatory T Cells Are Reduced During Anti-CD 25 Antibody Treatment of Multiple Sclerosis (2009) (3)
Virus-specific cytotoxic T lymphocytes in multiple sclerosis: a normal mumps virus response adds support for a distinct impairment in the measles virus response (1989) (3)
Neuroimaging and the Use of Magnetic Resonance in Multiple Sclerosis (2001) (3)
Multiple Sclerosis Therapeutics: The growing need for alternative clinical trial designs for multiple sclerosis (2011) (2)
Significance of autoreactive T cells in diseases such as multiple sclerosis using an innovative primate model. (1994) (2)
The Application of Magnetic Resonance Imaging to Phase II Trials in Multiple Sclerosis (1999) (2)
EXPRESSION OF A NOVEL CANDIDATE AUTOANTIGEN, X2 MBP, IN MULTIPLE SCLEROSIS (MS) LESIONS: 214 (1995) (2)
T‐cell Receptor Use in Multiple Sclerosis (1995) (2)
Book Review Multiple Sclerosis as a Neuronal Disease Edited by Stephen G. Waxman. 484 pp., illustrated. San Diego, Calif., Elsevier Academic Press, 2005. $170. 0-12-738761-7 (2005) (2)
Evaluation of magnetic resonance imaging sensitivity in patients with relapsing remitting multiple sclerosis: baseline versus Betaseron treatment trials. (1996) (2)
New criteria for the diagnosis of multiple sclerosis (2005) (2)
The importance of clinical trials in unraveling the mysteries of multiple sclerosis (2011) (2)
Toxic and Nutritional Disorders of Myelin (1999) (2)
T‐Cell Receptor α and β CDR3 Expression by Myelin Basic Protein‐Specific Human T‐Cell Clones (1995) (2)
Correlation with disease severity in multiple sclerosis in CDR3 regions of myelin basic protein-specific T cell receptors (1994) (1)
EFFECT OF VIRUS INFECTION OF ADULT HUMAN GLIAL CELLS ON EXPRESSION OF HLA MOLECULES: 47 (1989) (1)
The role of immunological response in infections of the central nervous system. (1974) (1)
Specificity and Functional Antigen Avidity Subsets Differ with Respect to Epitope + and Memory CD 45 RO + Naive CD 45 RA T Cells from + Human Autoreactive CD 4 (2000) (1)
Introduction to the Special Issue (2005) (1)
65 – Multiple sclerosis (2008) (1)
Mumps virus-specific cytotoxic T lympocyte responses can be mediated by class II MHC-restricted CD4+ cells (1987) (1)
DIFFERENTIAL EXPRESSION OF A NOVEL CANDIDATE AUTOANTIGEN, X2 MBP, IN MULTIPLE SCLEROSIS (MS) LESIONS (1996) (1)
T cell receptor usage in neurological disease: the case in multiple sclerosis (1992) (1)
From specificity to degeneracy to molecular mimicry: Antigen recognition of human autoreactive and pathogen-specific CD4+ T cells (1998) (1)
Comment on “Interleukin‐2/Interleukin‐2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation” (2012) (1)
Examination of the role of MRI in multiple sclerosis: a problem orientated approach. (2010) (1)
Immune mechanisms relating to viral infections of the nervous system (1988) (1)
Corrections: Autoreactive CD8^+ T-Cell Responses to Human Myelin Protein- Derived Peptides (1995) (1)
Clinical neuroimmunology: Multiple sclerosis (1987) (1)
Multiple Sclerosis Support the Etiologic Role of DRB5*01:01 in TCR/HLA-DRB5*01:01 Transgenic Mice Myelin Basic Protein-Specific (2012) (0)
Reply (1978) (0)
Reply (1992) (0)
Disorders Primarily Affecting Neurons with Secondary Involvement of Myelin (1999) (0)
Thesis Abstracts 1996 (1996) (0)
IDENTIFICATION OF INFLAMMATORY FACTORS THAT PROMOTE MYELINATION (2009) (0)
T-cell receptor alpha and beta CDR3 expression by myelin basic protein-specific human T-cell clones. (1995) (0)
Relapse May Serve as a Mediator Variable in Longitudinal Outcomes in Multiple Sclerosis (2016) (0)
Impaired measles-specific cytotoxic T-cell response in SSPE (1987) (0)
3D double inversion recovery imaging distinguishes in vivo final stage of chronic black holes in multiple sclerosis patients (2006) (0)
In vitro inhibition of MBP-specific T cell clones by interferon β (IFN-β) (1996) (0)
Optic Nerve Cross-Sectional Area Measurement with High-Resolution, Isotropic MRI in Optic Neuritis (P6.159) (2015) (0)
Detecting multiple sclerosis cortical lesions post-mortem using 7 Tesla Magnetic Resonance Imaging (2009) (0)
Activation of human class-II restricted T cell clones by short peptides (1998) (0)
Cerebrospinal Fluid Immunoglobulin Abnormalities in Multiple Sclerosis (1987) (0)
A MyelinBasicProteinPeptideIsRecognizedby CytotoxicT CellsintheContextofFourHLA DR 'hypesAssociatedwithMultipleSclerosis (1991) (0)
The Relationship Between Acute Disease Activity on MRI as Reflected by Blood-Brain Barrier Disruption and Clinical Measures of Disease Activity (2000) (0)
White Holes and Their Impact on Physical Disability in Patients with Multiple Sclerosis (2010) (0)
Re: GAMES issue. (2004) (0)
Chronic murine measles encephalitis-a strain depen- dent phenomenon. Abstr. (1979) (0)
Method for the management of multiple sclerosis (2003) (0)
Cloned measles virus-specific T lyn multiple sclerosis (2016) (0)
Brief Definitive Report Identification of a Specific Hla Dr2 Ia Molecule as a Restriction Element for Measles Virus- Specific Hla Class Ii-restricted Cytotoxic T Cell Clones (2003) (0)
Differential gene expression in multiple sclerosis lesions identified using cDNA microarrays (1998) (0)
A method for the treatment of multiple sclerosis (2003) (0)
Immunological Aspects of Multiple Sclerosis with Emphasis on the Potential Use of Autologous Hemopoietic Stem Cell Transplantation (2019) (0)
New aspects in the treatment of multiple sclerosis with Interferon beta-1b (1997) (0)
The Clinical and Social Impact of Interferon-β: The First Approved Therapy in Multiple Sclerosis (1999) (0)
IL-7 modified primary proliferation asa method for generation of antigen-specific T cell lines (TCL) preferentially from the pool of memory T cells (1998) (0)
Sjogren's syndrome central nervous system disease (SS-CNS) mimicking multiple sclerosis (MS) (1988) (0)
Measles virus-specific cytotoxic T cell responses to purified measles virus antigens (1985) (0)
Use-Dependent Plasticity in Patients with Multiple Sclerosis (2004) (0)
Alternative designs for multiple sclerosis clinical trials (2007) (0)
Reply from the authors: Ms in twins (1981) (0)
HIV testing in dialysis units: preventing the plague? (1989) (0)
FAILURE OF IMMATURE MICE TO DEVELOP CLINICAL SIGNS OF ACUTE EAE CORRELATES WITH APOPTOTIC CLEARANCE OF LYMPHOCYTES FROM THE CNS: 28 (1995) (0)
Multiple Sclerosis T Cells + High-Avidity Myelin-Specific CD 4 Expansion and Functional Relevance of (2004) (0)
Platform Presentations (2002) (0)
I. ADOPTIVE IMMUNIZATION OF IMNrUNOSUPPRESSED MICE [NFECTED WITH SINDBIS VIRUS* (2003) (0)
Reply (1996) (0)
Assessment of a “naive” vs “memory” origin of human autoreactive CD4+ T cell clones specific for myelin basic protein (MBP) (1998) (0)
Pathologic Findings in a Newly Described, Adult‐Onset Leukodystrophy (1990) (0)
SELECTIVE NEURONAL, DENDRITIC AND POSTSYNAPTIC LOCALIZATION OF VIRAL ANTIGEN IN MEASLES INFECTED INFECTED MICE (1978) (0)
Acquired Disorders of Myelin (1999) (0)
to TCR Ligand Potency Within MHC Molecule or Antigenic Peptide Contribution of Individual Amino Acids (1999) (0)
MS in twins (1981) (0)
Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial (2023) (0)
Diversity and Function of Human Class II MHC Antigens (1988) (0)
Oral session 30 — Multiple sclerosis (6) (2005) (0)
Longitudinal study of T cell receptor usage to myelin basic protein in multiple sclerosis patients (1994) (0)
Genetic Disorders of Myelin (1999) (0)
EXPLORING THE RELATIONS BETWEEN EMOTIONAL DISABILITY AND SUBCORTICAL ATROPHY IN PATIENTS WITH MULTIPLE SCLEROSIS (2009) (0)
Oral session 29 — Multiple sclerosis (5) (2005) (0)
Postural control and the clinical evaluation of patients with multiple sclerosis (1993) (0)

This paper list is powered by the following services:

Henry F. Mcfarland's Academic­Influence.com Rankings

Henry F. Mcfarland's Degrees

Why Is Henry F. Mcfarland Influential?

Henry F. Mcfarland's Published Works

Published Works

Henry F. Mcfarland's AcademicInfluence.com Rankings